![Stephen Thomas](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Thomas
Director/Board Member at ELIEM THERAPEUTICS, INC.
Net worth: 801 123 $ as of 31/05/2024
Network origin in Stephen Thomas first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Biotechnology | 8 | |
ValenzaBio, Inc.
![]() ValenzaBio, Inc. BiotechnologyHealth Technology ValenzaBio, Inc. develops safe and effective treatment options for patients with autoimmune and inflammatory diseases. The company is headquartered in Bethesda, MD.
1
| Subsidiary | Biotechnology | 1 |
Ichorion Therapeutics, Inc.
![]() Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ichorion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of treatments for rare diseases. It focuses on a pipeline of genetically-targeted therapies for inherited metabolic disorders known as Inborn Errors of Metabolism. The company was founded by Stephen Thomas on July 7, 2017 and is headquartered in New York, NY.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Stephen Thomas via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Convergence Pharmaceuticals Ltd.
![]() Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Founder Corporate Officer/Principal Founder | |
ARVINAS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Arvinas Operations, Inc.
![]() Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member Director/Board Member | |
Bridge Valley Ventures LLP
![]() Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
RA Capital Management LP (Private Equity)
![]() RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor Private Equity Investor | |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
University of Washington
![]() University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Graduate Degree | |
Clinton Health Access Initiative
![]() Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Lusaris Therapeutics, Inc.
![]() Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Biotechnology | Chief Executive Officer | |
Imbria Pharmaceuticals, Inc.
![]() Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Founder | |
Clear Creek Bio, Inc.
![]() Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
SYNTHORX, INC. | Biotechnology | Director/Board Member | |
RA Capital Management LP
![]() RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Portfolio Manager-Equities | |
H.I.G Capital LLC (Private Equity)
![]() H.I.G Capital LLC (Private Equity) Investment ManagersFinance H.I.G. Capital LLC (H.I.G Capital) is a private equity division of H.I.G. Capital LLC founded in 1993 by Sami W Mnaymneh and Anthony A Tamer. The firm is headquartered in Miami, Florida with offices in Europe, Latin America and Middle East. | Investment Managers | Private Equity Investor | |
Clinton Group, Inc.
![]() Clinton Group, Inc. Investment ManagersFinance Clinton Group, Inc. is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by George E. Hall in 1991 and is a subsidiary of Madison Avenue Capital Holdings, Inc., which is owned by CGI Holdings, Inc. Clinton Group serves as investment manager primarily for an offshore private investment fund, as well as pools of collateralized debt obligations (CDOs), collateralized bond obligations (CBOs) and other structured products for which the the firm as collateral manager. | Investment Managers | Corporate Officer/Principal | |
Superluminal Medicines Inc
![]() Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Biotechnology | Director/Board Member | |
Princeton University | College/University | Undergraduate Degree | |
H.I.G. BioHealth Partners LLC
![]() H.I.G. BioHealth Partners LLC Investment ManagersFinance H.I.G. BioHealth Partners LLC (H.I.G. BioHealth Partners) is a private equity and venture capital subsidiary of H.I.G. Ventures LLC founded in 1993. The firm is headquartered in Miami, Florida with additional offices around the globe. | Investment Managers | Private Equity Investor | |
Tang Capital Management LLC
![]() Tang Capital Management LLC Investment ManagersFinance Tang Capital Management LLC (Tang Capital) is an independent hedge fund manager headquartered in San Diego, California. The firm was founded by Kevin Tang in 2002. Tang Capital provides investment advice to high-net-worth clients. | Investment Managers | Analyst-Equity | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
Citadel Advisors LLC
![]() Citadel Advisors LLC Investment ManagersFinance Citadel Advisors LLC is a SEC-registered investment advisor and hedge fund manager headquartered in Miami, Florida. The firm was founded in 1990 by Kenneth Griffin and is wholly-owned by Citadel Advisors Holdings LP, ultimately held by GFH HFEVA LLC. Citadel Advisors manages private investment funds that are offered exclusively to sophisticated investors. | Investment Managers | Analyst-Equity | |
University of Virginia School of Law | College/University | Graduate Degree | |
Aliada Therapeutics, Inc.
![]() Aliada Therapeutics, Inc. BiotechnologyHealth Technology Aliada Therapeutics, Inc. is a neuroscience-focused company that aims to overcome the delivery hurdle in large molecule drug development. The company is based in Boston, MA. The company is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness. Aliada Therapeutics was founded by Sanjaya Singh, and the CEO is Adam Rosenberg. | Biotechnology | Chief Executive Officer | |
Seamless Therapeutics
![]() Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Packaged Software | Chairman | |
Harvard Medical School | College/University | Doctorate Degree | |
F. Hoffmann-La Roche Ltd.
![]() F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Sumitomo Pharma America, Inc.
![]() Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
GlaxoSmithKline LLC
![]() GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
FULCRUM THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Rochester Christian University | College/University | Undergraduate Degree | |
Wesleyan University | College/University | Doctorate Degree | |
SEELOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Evolution Research Group LLC
![]() Evolution Research Group LLC Miscellaneous Commercial ServicesCommercial Services Evolution Research Group LLC provides in-patient and out-patient clinical trial services to pharmaceutical companies. It specializes in psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency and hepatic impairment, and normal healthy volunteers. The company was founded in 2014 and is headquartered in New Providence, NJ. | Miscellaneous Commercial Services | Director/Board Member | |
New York Biotechnology Association, Inc.
![]() New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services New York Biotechnology Association, Inc. promotes the biotechnology industry. It supports the development and growth of New York State''s life science industry, and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. The company is headquartered in New York, NY. | Miscellaneous Commercial Services | Chairman | |
Eliem Therapeutics (UK) Ltd.
![]() Eliem Therapeutics (UK) Ltd. BiotechnologyHealth Technology Founded in 2019, Eliem Therapeutics (UK) Ltd. is a British company that engages in research and development on biotechnology. Part of Eliem Therapeutics, Inc., the company is based in Altrincham, UK. | Biotechnology | Director/Board Member | |
Université de Bordeaux | College/University | Graduate Degree | |
AVALO THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
H.I.G. BioVentures Advisors LLC | Corporate Officer/Principal | ||
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
University Of Dundee | College/University | Graduate Degree | |
INTERMEDIATE CAPITAL GROUP PLC | Financial Conglomerates | Corporate Officer/Principal | |
University of Illinois | College/University | Undergraduate Degree | |
BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of California, Los Angeles | College/University | Graduate Degree | |
GlaxoSmithKline, Inc.
![]() GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistics
International
United States | 38 |
United Kingdom | 9 |
Germany | 2 |
Switzerland | 2 |
France | 2 |
Sectoral
Health Technology | 25 |
Finance | 11 |
Consumer Services | 11 |
Commercial Services | 4 |
Technology Services | 2 |
Operational
Director/Board Member | 51 |
Corporate Officer/Principal | 26 |
Independent Dir/Board Member | 17 |
Chief Executive Officer | 10 |
Founder | 8 |
Most connected contacts
Insiders | |
---|---|
Liam Ratcliffe | 32 |
Andrew Levin | 22 |
Michael Solomon | 14 |
Adam Rosenberg | 13 |
Simon Tate | 9 |
Judith Dunn | 9 |
Valerie Morisset | 6 |
Patrick Crutcher | 5 |
Emily Pimblett | 4 |
Joanne Palmer | 3 |
- Stock Market
- Insiders
- Stephen Thomas
- Company connections